Retrophin Stock Price, News & Analysis (NASDAQ:RTRX)

$22.34 -0.63 (-2.74 %)
(As of 02/23/2018 01:47 AM ET)
Previous Close$22.97
Today's Range$22.32 - $23.39
52-Week Range$15.55 - $26.44
Volume155,906 shs
Average Volume263,159 shs
Market Capitalization$878.11 million
P/E Ratio-16.92
Dividend YieldN/A
Beta1.26

About Retrophin (NASDAQ:RTRX)

Retrophin logoRetrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:RTRX
CUSIPN/A
Phone+1-760-2608600

Debt

Debt-to-Equity Ratio0.15%
Current Ratio3.88%
Quick Ratio3.83%

Price-To-Earnings

Trailing P/E Ratio-16.9242424242424
Forward P/E Ratio-18.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$133.59 million
Price / Sales6.57
Cash Flow$0.57 per share
Price / Cash39.03
Book Value$8.16 per share
Price / Book2.74

Profitability

Trailing EPS($1.32)
Net Income$-47,900,000.00
Net Margins-33.79%
Return on Equity-10.13%
Return on Assets-5.94%

Miscellaneous

Employees135
Outstanding Shares39,310,000

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) issued its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.21. The biopharmaceutical company earned $40.34 million during the quarter, compared to analyst estimates of $40.51 million. Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. Retrophin's quarterly revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.09) earnings per share. View Retrophin's Earnings History.

Where is Retrophin's stock going? Where will Retrophin's stock price be in 2018?

2 brokerages have issued 12 month target prices for Retrophin's stock. Their forecasts range from $44.00 to $44.00. On average, they anticipate Retrophin's stock price to reach $44.00 in the next twelve months. View Analyst Ratings for Retrophin.

What are Wall Street analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:

  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (1/11/2018)
  • 2. BMO Capital Markets analysts commented, "We maintain our Outperform rating on RTRX shares following Retrophin's announcement to initiate a Phase III trial in 2H17 for Sparsentan. Our price target decreases to $45 from $46, as we push back Sparsentan estimates by two years, but increase our probability of success to 75% from 55%. We believe FDA agreement for proteinuria as an approvable endpoint removes significant uncertainty around Sparsentan's regulatory path as well as avoids a lengthy trial requiring eGFR or kidney survival as endpoints. We estimate Sparsentan peak sales (US only) of $1bn." (3/2/2017)

Who are some of Retrophin's key competitors?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:

  • Gary A. Lyons, Independent Chairman of the Board (Age 66)
  • Stephen J. Aselage, President, Chief Executive Officer, Director (Age 65)
  • Laura M. Clague CPA, Chief Financial Officer, Senior Vice President (Age 58)
  • Neil McFarlane, Chief Operating Officer (Age 44)
  • Elizabeth E. Reed, Senior Vice President, General Counsel and Corporate Secretary (Age 46)
  • William E. Rote Ph.D., Senior Vice President and Head of Research and Development (Age 54)
  • Roy D. Baynes M.D. Ph.D., Independent Director (Age 62)
  • Timothy P. Coughlin CPA, Independent Director (Age 50)
  • John W. Kozarich, Independent Director (Age 67)
  • Jeffrey A. Meckler, Independent Director (Age 50)

Who owns Retrophin stock?

Retrophin's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Consonance Capital Management LP (9.27%), BlackRock Inc. (8.46%), Perceptive Advisors LLC (6.80%), Macquarie Group Ltd. (3.41%), Jennison Associates LLC (2.45%) and Franklin Resources Inc. (2.24%). Company insiders that own Retrophin stock include Alvin Shih, Elizabeth E Reed, Jeffrey A Meckler, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Who sold Retrophin stock? Who is selling Retrophin stock?

Retrophin's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Franklin Resources Inc., Macquarie Group Ltd., Deutsche Bank AG, Two Sigma Investments LP, Bank of New York Mellon Corp, Quantitative Investment Management LLC and Two Sigma Advisers LP. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Neil F Mcfarlane and William E Rote. View Insider Buying and Selling for Retrophin.

Who bought Retrophin stock? Who is buying Retrophin stock?

Retrophin's stock was acquired by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, Bank of Montreal Can, GW&K Investment Management LLC, Virtus Fund Advisers LLC, Spark Investment Management LLC, Alliancebernstein L.P., Geode Capital Management LLC and Arrowstreet Capital Limited Partnership. View Insider Buying and Selling for Retrophin.

How do I buy Retrophin stock?

Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of Retrophin stock can currently be purchased for approximately $22.34.

How big of a company is Retrophin?

Retrophin has a market capitalization of $878.11 million and generates $133.59 million in revenue each year. The biopharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Retrophin employs 135 workers across the globe.

How can I contact Retrophin?

Retrophin's mailing address is 3721 Valley Centre Dr Ste 200, SAN DIEGO, CA 92130-3330, United States. The biopharmaceutical company can be reached via phone at +1-760-2608600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (RTRX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Retrophin (NASDAQ:RTRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.00$44.00$36.00$35.00
Price Target Upside: 77.85% upside77.85% upside45.51% upside97.18% upside

Retrophin (NASDAQ:RTRX) Consensus Price Target History

Price Target History for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ:RTRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017BMO Capital MarketsReiterated RatingBuy$44.00N/AView Rating Details
4/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/AView Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Retrophin (NASDAQ:RTRX) Earnings History and Estimates Chart

Earnings by Quarter for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ RTRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.25)($0.46)$40.51 million$40.34 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.24)($0.34)$37.36 million$38.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.22)$0.01$36.20 million$33.62 millionViewListenView Earnings Details
11/3/2016Q3$0.38($0.09)$34.84 million$33.95 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.08)$32.80 million$33.31 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.23 million$17.37 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)$8.35 millionViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
11/18/2013Q3 2013($0.33)ViewN/AView Earnings Details
9/16/2013Q2 2013($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Retrophin (NASDAQ:RTRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.28)($0.28)($0.28)
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.13)($0.13)($0.13)
Q4 20181($0.10)($0.10)($0.10)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Retrophin (NASDAQ:RTRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Retrophin (NASDAQ RTRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.87%
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ RTRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2018William E RoteSVPSell1,034$21.50$22,231.0011,156View SEC Filing  
1/5/2018Elizabeth E ReedSVPSell942$24.04$22,645.689,058View SEC Filing  
8/16/2017Neil F McfarlaneCOOSell1,378$22.50$31,005.0013,622View SEC Filing  
11/22/2016Steve AselageCEOSell8,200$21.12$173,184.00248,756View SEC Filing  
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00158,334View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50167,084View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.0052,000View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.0047,000View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50175,834View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50184,584View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.0050,000View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00193,334View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Retrophin (NASDAQ RTRX) News Headlines

Source:
DateHeadline
Retrophin Inc (RTRX) SVP Sells $22,231.00 in StockRetrophin Inc (RTRX) SVP Sells $22,231.00 in Stock
www.americanbankingnews.com - February 16 at 10:22 PM
Retrophin to Report Fourth Quarter and Full Year 2017 Financial ResultsRetrophin to Report Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 14 at 9:32 AM
Retrophin (RTRX) vs. Lipocine (LPCN) Critical AnalysisRetrophin (RTRX) vs. Lipocine (LPCN) Critical Analysis
www.americanbankingnews.com - February 6 at 1:19 PM
Retrophin Inc (RTRX) Receives Consensus Rating of "Hold" from BrokeragesRetrophin Inc (RTRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 4 at 3:30 AM
Retrophin (RTRX) Rating Lowered to Sell at ValuEngineRetrophin (RTRX) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - February 3 at 2:44 PM
Retrophin (RTRX) Lowered to Hold at BidaskClubRetrophin (RTRX) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 3 at 11:58 AM
Retrophin to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceRetrophin to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 2 at 9:34 AM
Are Options Traders Betting on a Big Move in Retrophin (RTRX) Stock?Are Options Traders Betting on a Big Move in Retrophin (RTRX) Stock?
finance.yahoo.com - January 15 at 3:23 PM
Leerink Swann Analysts Raise Earnings Estimates for Retrophin Inc (RTRX)Leerink Swann Analysts Raise Earnings Estimates for Retrophin Inc (RTRX)
www.americanbankingnews.com - January 15 at 1:40 AM
Research Analysts Offer Predictions for Retrophin Incs Q1 2018 Earnings (RTRX)Research Analysts Offer Predictions for Retrophin Inc's Q1 2018 Earnings (RTRX)
www.americanbankingnews.com - January 12 at 9:34 AM
Retrophin (RTRX) Cut to "Sell" at Zacks Investment ResearchRetrophin (RTRX) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 11 at 9:02 AM
Retrophin Inc (RTRX) Receives Consensus Recommendation of "Hold" from AnalystsRetrophin Inc (RTRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 10 at 3:08 AM
$40.50 Million in Sales Expected for Retrophin Inc (RTRX) This Quarter$40.50 Million in Sales Expected for Retrophin Inc (RTRX) This Quarter
www.americanbankingnews.com - January 9 at 6:40 AM
Elizabeth E. Reed Sells 942 Shares of Retrophin Inc (RTRX) StockElizabeth E. Reed Sells 942 Shares of Retrophin Inc (RTRX) Stock
www.americanbankingnews.com - January 9 at 12:46 AM
Retrophin Provides Corporate Update and 2018 OutlookRetrophin Provides Corporate Update and 2018 Outlook
finance.yahoo.com - January 8 at 11:11 AM
 Analysts Expect Retrophin Inc (RTRX) Will Announce Earnings of $0.17 Per Share Analysts Expect Retrophin Inc (RTRX) Will Announce Earnings of $0.17 Per Share
www.americanbankingnews.com - January 7 at 3:30 PM
Retrophin (RTRX), Censa Pharmaceuticals Enter into Pact to Advance CNSA-001 for Treatment of PKURetrophin (RTRX), Censa Pharmaceuticals Enter into Pact to Advance CNSA-001 for Treatment of PKU
www.streetinsider.com - January 6 at 7:58 AM
Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)
finance.yahoo.com - January 5 at 3:24 PM
Retrophin (RTRX) Upgraded by Zacks Investment Research to "Hold"Retrophin (RTRX) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 4 at 3:00 PM
Commit To Purchase Retrophin At $12.50, Earn 6% Using OptionsCommit To Purchase Retrophin At $12.50, Earn 6% Using Options
www.nasdaq.com - January 2 at 3:27 PM
Retrophin (RTRX) Rating Lowered to Hold at BidaskClubRetrophin (RTRX) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 30 at 1:26 PM
Retrophin to Present at the 36th Annual J.P. Morgan Healthcare ConferenceRetrophin to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 29 at 9:25 AM
Ex-lawyer for pharma executive Shkreli convicted of aiding fraud schemeEx-lawyer for pharma executive Shkreli convicted of aiding fraud scheme
www.reuters.com - December 28 at 4:30 PM
Martin Shkreli’s ex-lawyer found guilty of aiding fraud schemeMartin Shkreli’s ex-lawyer found guilty of aiding fraud scheme
www.marketwatch.com - December 28 at 4:30 PM
Ex-lawyer for pharma exec Shkreli convicted of aiding fraud schemeEx-lawyer for pharma exec Shkreli convicted of aiding fraud scheme
finance.yahoo.com - December 27 at 8:15 PM
[$$] Martin Shkreli’s Former Lawyer Convicted of Aiding Fraud Scheme[$$] Martin Shkreli’s Former Lawyer Convicted of Aiding Fraud Scheme
finance.yahoo.com - December 27 at 8:15 PM
Martin Shkrelis ex-lawyer found guilty of financial fraudMartin Shkreli's ex-lawyer found guilty of financial fraud
marketbeat.com - December 27 at 6:48 PM
Martin Shkrelis ex-lawyer is convicted of aiding him in fraud schemeMartin Shkreli's ex-lawyer is convicted of aiding him in fraud scheme
www.latimes.com - December 27 at 5:39 PM
Shkreli’s Ex-Lawyer Convicted of Aiding Him in Fraud SchemeShkreli’s Ex-Lawyer Convicted of Aiding Him in Fraud Scheme
finance.yahoo.com - December 27 at 3:15 PM
ETFs with exposure to Retrophin, Inc. : December 27, 2017ETFs with exposure to Retrophin, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 3:15 PM
Financial Survey: Spring Bank Pharmaceuticals (SBPH) versus Retrophin (RTRX)Financial Survey: Spring Bank Pharmaceuticals (SBPH) versus Retrophin (RTRX)
www.americanbankingnews.com - December 26 at 11:54 PM
Retrophin, Inc. :RTRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Retrophin, Inc. :RTRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 1:06 PM
 Analysts Anticipate Retrophin Inc (RTRX) Will Announce Quarterly Sales of $40.50 Million Analysts Anticipate Retrophin Inc (RTRX) Will Announce Quarterly Sales of $40.50 Million
www.americanbankingnews.com - December 24 at 2:24 PM
Retrophin Inc (RTRX) Expected to Announce Earnings of $0.17 Per ShareRetrophin Inc (RTRX) Expected to Announce Earnings of $0.17 Per Share
www.americanbankingnews.com - December 22 at 10:10 AM
Retrophin (RTRX) & Regenxbio (RGNX) Head to Head ComparisonRetrophin (RTRX) & Regenxbio (RGNX) Head to Head Comparison
www.americanbankingnews.com - December 19 at 7:10 PM
Options Traders Expect Huge Moves in Retrophin (RTRX) StockOptions Traders Expect Huge Moves in Retrophin (RTRX) Stock
finance.yahoo.com - December 18 at 3:23 PM
Trial of Martin Shkreli's lawyer interrupted by 'serious' claims about government officialTrial of Martin Shkreli's lawyer interrupted by 'serious' claims about government official
finance.yahoo.com - December 15 at 3:24 PM
Comparing Retrophin (RTRX) & Its RivalsComparing Retrophin (RTRX) & Its Rivals
www.americanbankingnews.com - December 11 at 3:34 PM
Retrophin (RTRX) and Its Competitors Financial ReviewRetrophin (RTRX) and Its Competitors Financial Review
www.americanbankingnews.com - December 6 at 5:30 PM
A Martin Shkreli Trial Without the Outbursts, Anger or `TrashyA Martin Shkreli Trial Without the Outbursts, Anger or `Trashy'
finance.yahoo.com - December 6 at 3:23 PM
 Brokerages Expect Retrophin, Inc. (RTRX) Will Announce Quarterly Sales of $40.50 Million Brokerages Expect Retrophin, Inc. (RTRX) Will Announce Quarterly Sales of $40.50 Million
www.americanbankingnews.com - December 6 at 9:50 AM
$0.17 EPS Expected for Retrophin, Inc. (RTRX) This Quarter$0.17 EPS Expected for Retrophin, Inc. (RTRX) This Quarter
www.americanbankingnews.com - December 4 at 1:30 PM
Head to Head Contrast: Retrophin (RTRX) & The CompetitionHead to Head Contrast: Retrophin (RTRX) & The Competition
www.americanbankingnews.com - December 2 at 3:06 PM
Retrophin to Present at the BMO 2017 Prescriptions for Success Healthcare ConferenceRetrophin to Present at the BMO 2017 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 1 at 8:15 AM
Retrophin, Inc. (RTRX) Given Consensus Recommendation of "Buy" by AnalystsRetrophin, Inc. (RTRX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 21 at 3:52 AM
Retrophin, Inc. (RTRX) Cut to Sell at ValuEngineRetrophin, Inc. (RTRX) Cut to Sell at ValuEngine
www.americanbankingnews.com - November 20 at 10:20 PM
Analyzing Retrophin (RTRX) and Its RivalsAnalyzing Retrophin (RTRX) and Its Rivals
www.americanbankingnews.com - November 20 at 3:09 AM
Retrophin, Inc. (RTRX) Expected to Post Earnings of $0.17 Per ShareRetrophin, Inc. (RTRX) Expected to Post Earnings of $0.17 Per Share
www.americanbankingnews.com - November 16 at 1:04 AM
Zacks Investment Research Lowers Retrophin, Inc. (RTRX) to Strong SellZacks Investment Research Lowers Retrophin, Inc. (RTRX) to Strong Sell
www.americanbankingnews.com - November 14 at 7:50 AM
William Blair Equities Analysts Reduce Earnings Estimates for Retrophin, Inc. (RTRX)William Blair Equities Analysts Reduce Earnings Estimates for Retrophin, Inc. (RTRX)
www.americanbankingnews.com - November 13 at 2:14 AM

SEC Filings

Retrophin (NASDAQ:RTRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Retrophin (NASDAQ:RTRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Retrophin (NASDAQ RTRX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.